What we do_T-MAXIMUM Biotech

What we do

Pioneering the Future of Medicine with Engineered T Cells

At T-MAXIMUM we are at the forefront of a medical revolution, harnessing the transformative potential of engineered T cells to address diseases once considered
untreatable.

Our mission is to reshape the landscape of modern medicine by developing innovative therapies that bring hope and healing to patients worldwide.

Scientific Rationale Supporting Pipeline Development

The development of our pipeline is guided by extensive advances in understanding the role of the tumor immune microenvironment in regulating therapeutic response and resistance.

Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematological malignancies; however, its efficacy in solid tumors remains limited. Previous studies have identified multiple barriers to CAR-T therapy in solid tumors, including inefficient T cell infiltration, antigen heterogeneity, and, most importantly, an immunosuppressive tumor microenvironment.

The tumor microenvironment has been shown to actively inhibit CAR-T cell function through multiple mechanisms, including suppressive immune cell populations, inhibitory signaling pathways, and altered metabolic conditions that impair T cell persistence and cytotoxicity.

In particular, tumor-associated macrophages, especially M2-polarized macrophages, have been reported to promote therapeutic resistance through secretion of factors such as hepatocyte growth factor (HGF), leading to activation of oncogenic signaling pathways and supporting tumor progression.

Together, these findings suggest that effective CAR-T therapy for solid tumors requires not only tumor targeting, but also modulation of the tumor microenvironment.

Our pipeline reflects this strategy by incorporating microenvironment-modulating approaches, including combination with agents such as bevacizumab, as well as advanced delivery systems designed to enhance therapeutic activity within the tumor microenvironment.

Representative studies in this area include:

1. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013 Nov;19(11):1423-37. doi: 10.1038/nm.3394IF: 50.0 Q1 . PMID: 24202395; PMCID: PMC3954707.

2.June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711IF: 45.8 Q1 . PMID: 29567707.

3.Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, Li Y, Deng H, Wu Y, Li M, Li JL. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 2019 Jul;121(1):22-33. doi: 10.1038/s41416-019-0482-x. Epub 2019 May 27. PMID: 31130723; PMCID: PMC6738111.

4.Gao Y, Zhang Z, Ye D, Li Q, Wen Y, Ma S, Zheng B, Chen L, Yao Y. Association of HTR1F with Prognosis, Tumor Immune Microenvironment, and Drug Sensitivity in Cancer: A Multi-Omics Perspective. Biomedicines. 2025 Sep 11;13(9):2238. doi: 10.3390/biomedicines13092238IF: 3.9 Q1 . PMID: 41007799; PMCID: PMC12467612.

5.Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025 Apr 14;43(4):665-679. doi: 10.1016/j.ccell.2025.03.019IF: 44.5 Q1 . PMID: 40233718.

These advances have played an important role in shaping the conceptual framework underlying the design of our pipeline programs. Accordingly, our pipeline reflects the integration of CAR-T cell therapy with tumor microenvironment–targeted strategies, as supported by these representative studies and related technological developments.

Targeted Cancer Treatment: We specialize in CAR-T cell therapy, an advanced approach that engineers T cells to specifically recognize and eliminate malignant cells. This modality has demonstrated significant efficacy in hematologic malignancies, providing new therapeutic options for patients who have exhausted conventional treatments.

Expanding into Adjuvant Therapy: We are pioneering the application of allogeneic CAR-T cell therapy in earlier stages of cancer treatment, particularly as adjuvant and neoadjuvant interventions. Administered following curative procedures (e.g., tumor resection) or prior to primary therapies, CAR-T therapy aims to eradicate micrometastatic disease, reduce tumor burden, and ultimately decrease recurrence risk while improving cure rates. The "off-the-shelf" nature of allogeneic CAR-T therapy enables rapid and scalable deployment, making it ideally suited for these critical therapeutic windows.

Addressing Key Challenges in Engineered T Cell Therapies

Safety and Efficacy: We prioritize patient safety by advancing strategies to mitigate treatment-associated adverse events, such as cytokine release syndrome (CRS) and neurotoxicity, while optimizing therapeutic efficacy.

Simplifying Manufacturing and Treatment: Through the integration of cutting-edge technologies, including CRISPR/Cas9 gene editing, we are streamlining the engineering and production of T cells to improve precision, consistency, and clinical outcomes.

Enhancing Accessibility: We are developing “off-the-shelf” allogeneic engineered T cells to enable scalable manufacturing, reduce treatment costs, and broaden patient access to these transformative therapies.

Overcoming Allogeneic CAR-T Cell Rejection

A significant challenge in broadening the applicability of CAR-T therapy has been the development of allogeneic CAR-T cells – those derived from donors rather than the patients themselves. While allogeneic CAR-T cells hold the promise of off-the-shelf availability, making treatment more accessible and reducing time-to-treatment, they also face the hurdle of immune rejection.

To address this, various technical paths have been explored within the industry, such as gene editing to remove T cell receptors (TCRs) that might cause graft-versus-host disease (GVHD), and the insertion of suicide genes to eliminate the CAR-T cells if necessary.

We have charted our unique course through these challenges. Our proprietary technologies not only address the problem of rejection more effectively but also enhance the persistence and efficacy of allogeneic CAR-T cells in the patient's body.

The strides we've made in the complex field of cell drug development are largely attributable to our executive team's deep well of experience and expertise. This team, comprising industry veterans with a proven track record in cell therapy development, brings together a wealth of knowledge in biotechnology, pharmaceuticals, and clinical research.